Professor Stephanie Watson: Ledger

Stories naming Professor Stephanie Watson. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Role	Organisation	Sources
	Save Sight Institute	Brandon BioCatalyst portfolio, Brandon Capital portfolio
Professor	The University of Sydney	Brandon BioCatalyst portfolio, Brandon Capital portfolio

Series A $13m

Australian Phase II trial commences for potential world-first treatment of viral conjunctivitis

Okogen has begun Australian Phase II trials of its conjunctivitis therapy OKG-0301 across multiple sites, with Brandon Capital's MRCF having invested in the biotech's Series A in December 2017.

Brandon Capital portfolio Thu 31 Jan 2019 Okogen Albury Eye Clinic Centre for Eye Research Australia Hobart Eye Clinic Lions Eye Institute Medical Research Commercialisation Fund (MRCF)New South Wales Department of Health and Medical Research Royal Adelaide Hospital Royal Victorian Eye and Ear Hospital Save Sight Institute Sydney Eye Hospital The University of Sydney UNSW Sydney Brandon Capital Brian M. Strem Professor Stephanie Watson

Also Brandon BioCatalyst portfolio

Professor Stephanie Watson

Roles

Coverage

Australian Phase II trial commences for potential world-first treatment of viral conjunctivitis